Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 23, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - October 23, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/23/14 - Biopharmaceutical Contract Manufacturing: HighTech Business Decisions' New Report Indicates Improving Demand for Outsource Services
The biopharmaceutical contract manufacturing market has grown at a compound annual rate approaching 10% over the last three years. The market for biopharmaceutical contract manufacturing services will reach US $2.8 billion this year. William Downey, president of HighTech Business Decisions, explains, We extensively interviewed 50 executives at..
10/23/14 - Harvoni Approved For The Treatment Of Chronic Hepatitis C; TapImmune Provides Update on PolyStart? Vaccine Platform
FDA announced October 10, 2014 that Gilead Sciences Harvoni product was approved for the treatment of chronic hepatitis C, genotype 1 infection in adults. Sofosbuvir was approved by the FDA under the trade name Sovaldi in December 2013. Harvoni is a product of Gilead Sciences, based in Foster City, California.======================== TapIm
10/23/14 - Ky. lawsuit against OxyContin maker could deal huge blow [National Iraqi News Agency (Iraq)]
Today's docket includes a woman convicted of public intoxication, an accused trafficker of painkillers, and a procedural matter involving Purdue Pharma, a multibillion-dollar pharmaceutical company based in Stamford, Conn., that's effectively accused of laying waste to this Appalachian coal town. In this county courthouse in southeastern Kentucky,
10/23/14 - Similar, but different [China Daily: Hong Kong Edition]
Ming Yeung talks to a few experts in the field to find out whether these drugs are as safe as they are affordable. President of the Society of Hospital Pharmacists of Hong Kong, William Chui Chun-ming, argued that savings on healthcare in Hong Kong could tally to HK $230 million a year from now until 2022- if public health authorities introduced mo
10/22/14 - "Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014" Is Now Available at Fast Market Research
Fast Market Research recommends " Arbor Pharmaceuticals, LLC.- Product Pipeline Review- 2014" from Global Markets Direct, now availableBoston, MA 10/22/2014 Global Markets Direct's,' Arbor Pharmaceuticals, LLC.- Product Pipeline Review- 2014', provides an overview of the Arbor Pharmaceuticals, LLC.' s pharmaceutical research and development f
10/22/14 - "Intravenous Formulation with Water-Soluble Cocrystals of Acetylsalicylic Acid and Theanine" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Brittain, Harry G.; Felice, Philip V., filed on May 21, 2014, was made available online on October 9, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Theaprin Pharmaceutic
10/22/14 - 'Liberians Won't Be Used As Guinea Pigs' for Ebola Trial Drugs Not Approved
The Liberia Medicines& Health Products Regulatory Authority has strongly warned pharmaceutical companies and others, who are trying to bring in "Ebola drugs/medicines," for trial purposes, that Liberians won't be used as Guinea pigs. LMHRA, which released a statement yesterday, is the Government of Liberia's arm that has the statutory mandate to re
10/22/14 - A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment Hi
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting...
10/22/14 - Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on chronic kidney disease mineral and bone disorder with Ravi Thadhani, M.D., M.P.H.
10/22/14 - AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results
AcelRx Pharmaceuticals, Inc. today announced that results from the IAP310 study have been published in Regional Anesthesia and Pain Medicine, a peer-reviewed journal with broad, multidisciplinary readership. IAP310 was a randomized, placebo-controlled, Phase 3 trial evaluating the safety and efficacy of Zalviso, also referred to as the sufentanil
10/22/14 - Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin
DUBLIN and BOSTON, Oct. 22, 2014/ PRNewswire/ Actavis plc, a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health, Inc., which is developing relamorelin, a peptide ghrelin agonist, for t
10/22/14 - Alexion Announces the Passing of Max Link, Ph.D., Chairman of the Company's Board of Directors
By a News Reporter-Staff News Editor at Biotech Week Alexion Pharmaceuticals, Inc. announced that Max Link, Ph.D., Chairman of the Board of Directors of Alexion, passed away unexpectedly on October 5 while traveling on business. Dr. Link, a globally respected leader of companies in the pharmaceutical, biotechnology and medical device industries o
10/22/14 - Alkermes New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA
Alkermes plc today announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for aripiprazole lauroxil, the company s investigational, novel, once-monthly injectable atypical antipsychotic for the treatment of schizophrenia. Under the Prescription Drug User Fee Act, the FDA s target action date for
10/22/14 - ALS ACT, The ALS Association, and the Northeast ALS Consortium Issue Request for Proposals for Phase II Clinical Development of Novel, High-Potential Treatments for ALS
WASHINGTON, Oct. 22, 2014/ PRNewswire-USNewswire/ ALS ACT, The ALS Association, and the T ranslational Re search A dvancing T herapy ALS Northeast ALS Consortium clinical trials network are pleased to announce a call for phase II clinical trial applications for novel, high-potential treatments in amyotrophic lateral sclerosis. The call for clinic
10/22/14 - Arch Biopartners Rolls Out Metablok [Professional Services Close - Up]
Arch Biopartners reported the introduction of Metablok, a new drug candidate in its development pipeline as a potential treatment for sepsis and cancer metastasis. Jennifer Rahn and their University of Calgary colleague, Dr. Arch Biopartners is a portfolio based biotechnology company.
10/22/14 - Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other solid tumors. Atara Biotherapeutics, Inc. is a drug development
10/22/14 - Bavarian Nordic Announces Expanded Collaboration with Janssen on MVA-BN for Additional Infectious Disease Targets
KVISTGAARD, Denmark, October 22, 2014- Bavarian Nordic A/S announced today that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson& Johnson, to expand the collaboration announced earlier today to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undis
10/22/14 - Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
Under the terms of the agreement, Bavarian Nordic will grant Janssen an exclusive license for its multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus. In addition, Bavarian Nordic will scale up its production and is targeting to manufacture more than 1 million doses of the vaccine valued at U
10/22/14 - Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN Ebola Vaccine
*Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson& Johnson licenses MVA-BN-based Ebola/ Marburg vaccine from Bavarian Nordic* Bavarian Nordic will scale up and is targeting to manufacture more than 1 million doses of the prophylactic vaccine in 2015 for clinical trials and emergency use in the current Ebola outbreak in W
10/22/14 - Biocon Q2 FY15 Revenues at 773 Crore, PAT at 102 Crore [Global Data Point]
?Biocon's partner Mylan begins multicenter phase III clinical trials for insulin glargine in the United States.? Biocon, through its subsidiary Biocon Research Limited, buys back GE Equity International Mauritius' s 7.69% stake in Syngene for Rs. 215.38 Crore. Subsequently, it enters into an agreement to sell 10% to Silve r Leaf Oak Limited, va
10/22/14 - bioMerieux Works With FDA For Approval Of Its Ebola Screening Test [Global Data Point]
bioMerieux spokeswoman Suzanne Jones said that since the FilmArray system was solely developed for environmental surveillance, it is necessary for the company to demonstrate the US Food and Drug Administration evidence that the test could be used clinically.&# x0D;.
10/22/14 - Blaze Bioscience Announces NCI SBIR Phase II Funding for Clinical Trial of Tumor Paint? BLZ-100 in Sarcoma
By a News Reporter-Staff News Editor at Biotech Week Blaze Bioscience, Inc., a biotechnology company focused on guided cancer therapy, announced that the company has been awarded a $1.5 million Small Business Innovation Research Phase II contract from the National Cancer Institute to study Tumor Paint BLZ-100 in patients with soft tissue sarcoma1
10/22/14 - BRIEF: Mylan adjusts terms of Abbott Labs deal [Pittsburgh Post-Gazette]
Oct. 22 Cecil- based generic drug giant Mylan Inc. said in a government filing today that it still plans to complete its deal to buy a chunk of Abbott Laboratories' overseas generics business in the first quarter next year and reincorporate in the Netherlands, but the two companies have slightly adjusted the terms of the transaction. Under the ne
10/22/14 - Bristol-Myers Squibb Statement about Asunaprevir in the U.S.
By a News Reporter-Staff News Editor at Biotech Week Given the rapidly evolving hepatitis C treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1 b patients in the United States and
10/22/14 - Broda Receives US Patent for Thermal-Reversible Hydrogel Drug Delivery System [Global Data Point]
The patent covers the Company's key IntelliGel supramolecular drug delivery technology platform, compositions for pharmaceutical, cosmetic and personal care applications, and methods of making such compositions.&# x0D;.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


The Diversion of Controlled Substances and the Law
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement